Evaluating the Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates on Durable LVAD Support

Highlight

• The 2018 OPTN policy decreased prioritization of adult heart transplant candidates with durable LVADs.
• The 2025 OPTN policy proposes status upgrades at 6 and 8 years of LVAD support to expedite transplantation.
• Data show most LVAD-supported candidates experience complications or transplantation within 6 years.
• Only a small subset (4.7%) of the waitlist would benefit instantaneously from the new policy status changes.

Study Background

Heart transplantation remains the gold standard treatment for selected patients with end-stage heart failure. Durable left ventricular assist devices (LVADs) serve as bridge-to-transplant therapy to stabilize patients awaiting transplantation. However, LVAD-related complications such as infection, thrombosis, or device malfunction often arise, influencing transplant candidacy and prioritization.

In October 2018, the Organ Procurement and Transplantation Network (OPTN) revised the adult heart allocation policy, markedly lowering transplant priority status for candidates supported by durable LVADs who were previously listed at higher urgency statuses. This change aimed to better reflect contemporary clinical outcomes but extended waiting times for stable LVAD patients.

Recognizing the risk that long-term LVAD support carries increasing complications, the OPTN approved a status escalation policy effective June 1, 2025, granting stable LVAD patients status upgrades at 6 years (Status 3) and 8 years (Status 2) post-implantation. The intent is to facilitate earlier transplantation before clinical deterioration.

Study Design

Authors Ahn et al. conducted a retrospective cohort analysis using OPTN registry data from adult heart transplant candidates implanted with durable LVADs between October 18, 2018 and May 31, 2025. The cohort consisted of 4967 adult patients listed for heart transplantation with durable LVAD support.

The study employed competing risk analysis to estimate the cumulative incidence of LVAD-related complications, including devicespecific adverse events that justified status upgrades by transplant centers. Transplantation and waitlist removal before complications were considered competing events.

Additionally, the authors modeled the anticipated impact of implementing the OPTN’s 2025 policy on the distribution of transplant waiting list statuses for patients on durable LVADs beyond six years.

Key Findings

Among the 4967 patients studied, transplant centers submitted 2879 formal justifications for status upgrades related to LVAD complications on behalf of 1812 patients, indicating a 36.5% complication-driven status escalation rate.

At six years after LVAD implantation, the cumulative incidence of experiencing LVAD-related complications or receiving a status upgrade was 42.1% (95% CI: 40.5%-43.8%). Meanwhile, the cumulative incidence of undergoing transplantation by six years was 36.0% (95% CI: 34.6%-37.6%).

Among 3779 patients not censored administratively (e.g., transplanted or removed), only 47 (1.2%) remained active on the waitlist at 6 years post-LVAD implantation, underscoring that almost all candidates had either progressed to transplantation, experienced complications warranting status upgrades, or been delisted.

If the OPTN 6- to 8-year status escalation policy were implemented on June 1, 2025, simulations suggested that only 4.7% of the waitlist would experience immediate status changes based solely on time thresholds.

Expert Commentary

This study provides an important real-world perspective on the natural history and clinical trajectory of adult heart transplant candidates supported with durable LVADs under contemporary allocation policies. It reveals that the majority of candidates do not remain stable without complications beyond six years, limiting the proposed effect of time-based automatic status escalations.

While the 6- to 8-year status upgrade policy aims to reduce the risk of waiting too long with an LVAD, the data highlight that most candidates have already experienced complications or transplantation before reaching this time point. Consequently, the new policy may principally benefit a very small subset of stable patients.

Future research should consider integrating individualized risk stratification, incorporating clinical markers and device-related event history, rather than relying solely on duration of support. Furthermore, strategies to reduce LVAD complications and optimize timing for transplantation remain paramount.

Finally, the study’s robust use of competing risk methodology enhances the validity of the findings, but generalizability may be limited to the US transplant system and durable LVAD technologies prevalent during the study period.

Conclusion

The 2025 OPTN policy granting automatic status escalations at 6 and 8 years post durable LVAD implantation is unlikely to significantly alter transplant waitlist dynamics. Almost all LVAD-supported candidates experience clinical events prompting status upgrades or transplantation within 6 years. Thus, this policy will likely affect only a small fraction of the waitlist.

Clinicians and transplant programs should continue to prioritize early identification and management of LVAD complications. Additional research is needed to develop more nuanced prioritization frameworks that reflect the complex risk profiles and timelines of LVAD-supported heart transplant candidates.

Funding and ClinicalTrials.gov

No specific funding information was disclosed for this analysis. The study utilizes national registry data from OPTN with no clinical trial registration.

References

1. Ahn DJ, Attia A, Nakayama T, Narang N, Khush KK, Parker W, Sasaki K. Potential Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates With Durable LVADs. Circulation Heart Fail. 2026 Jun 23:e013854. PMID: 42335275.

2. OPTN Final Rule and Policies, Organ Procurement and Transplantation Network. Available at: https://optn.transplant.hrsa.gov/governance/policies/

3. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. The Fourth INTERMACS Annual Report: Risk Factor Analysis for Late Death after Continuous-Flow Mechanical Circulatory Support. J Heart Lung Transplant. 2013 Apr;32(4): 361-72.

4. Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Yuzefpolskaya M, et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med. 2017;376(5):440-450.